Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

Abstract

Severe Streptococcus pneumoniae infections are frequent complications after hematopoietic stem cell transplant (HSCT). A 3-dose regimen of 13-valent pneumococcal conjugate vaccine, starting 3–6 months after HSCT and followed by a booster dose, may be required for adequate protection.

How I vaccinate blood and marrow transplant recipients

“…We interpret this to include BMT recipients at least until they reach the milestone of being 6 months off all IST. The nuances of age-related HAV and HBV vaccine dosing and use of combination vaccines are detailed in Tables 1 and 2 (see also sFAQs [16][17][18][19][20][21][22]. HPV FAQ 9: why is vaccination against HPV advised for young BMT recipients?…”

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

“…103 Prevnar is more immunogenic than Pneumovax secondary to inducing more durable, T-cell dependent memory responses. 104,105 Unless a patient is severely immunocompromised, Prevnar should be started at 6 months post HCT for a total of three doses, each administered two months apart. 105,106 One dose of Pneumovax should be given 6 to 12 months after the last Prevnar dose.…”

“…104,105 Unless a patient is severely immunocompromised, Prevnar should be started at 6 months post HCT for a total of three doses, each administered two months apart. 105,106 One dose of Pneumovax should be given 6 to 12 months after the last Prevnar dose. 106,107 The recent 10-year decline in invasive pneumococcal disease among patients with hematologic malignancies in the US coincides with incorporation of Prevnar in universal childhood immunization.…”

Guillain-Barré syndrome following heart transplantation complicated by myocardial infarction following treatment with IVIg

“…Other reported causes include infection with EBV, human herpes virus 6, and coccidioides, while a few case reports have implicated vaccines (pneumococcal and influenza) and calcineurin inhibitors (both tacrolimus and cyclosporine). [3,[16][17][18][19][20][21][22] Given the prevalence in prior case reports and the temporal relationship of CMV viremia in the present case, we believe our patient most likely developed GBS related to his CMV infection. Table 3 contains a comprehensive list of prior cases of CMV associated GBS following transplantation.…”

“…At time of follow up with neurology one year later, his symptoms had resolved. [5][6][7][8][9][10][11][12][13][14][15] 18 EBV [16,17] 2 HHV-6 [18] 1 Coccidioidomycosis [19] 1 Pneumococcal vaccine [20] 1 Influenza vaccine [21] 1 Tacrolimus [3,22] 2 Cyclosporine [23][24][25] 3 C. jejuni [26,27] 2 Note. CMV = Cytomegalovirus; EBV = Ebstein-Barr virus; HHV = Human Herpes virus; C. jejuni = Campylobacter jejuni.…”